These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

341 related articles for article (PubMed ID: 24713173)

  • 1. Treating beyond symptoms with a view to improving patient outcomes in inflammatory bowel diseases.
    Sandborn WJ; Hanauer S; Van Assche G; Panés J; Wilson S; Petersson J; Panaccione R
    J Crohns Colitis; 2014 Sep; 8(9):927-35. PubMed ID: 24713173
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Are we under- or mistreating patients at the time of presentation?
    Fish S; Baldassano R
    Dig Dis; 2014; 32(4):364-9. PubMed ID: 24969281
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Moving towards disease modification in inflammatory bowel disease therapy.
    Allen PB; Peyrin-Biroulet L
    Curr Opin Gastroenterol; 2013 Jul; 29(4):397-404. PubMed ID: 23695427
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management Strategies to Improve Outcomes of Patients With Inflammatory Bowel Diseases.
    Colombel JF; Narula N; Peyrin-Biroulet L
    Gastroenterology; 2017 Feb; 152(2):351-361.e5. PubMed ID: 27720840
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcomes and Strategies to Support a Treat-to-target Approach in Inflammatory Bowel Disease: A Systematic Review.
    Colombel JF; D'haens G; Lee WJ; Petersson J; Panaccione R
    J Crohns Colitis; 2020 Feb; 14(2):254-266. PubMed ID: 31403666
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimising monitoring in the management of Crohn's disease: a physician's perspective.
    Papay P; Ignjatovic A; Karmiris K; Amarante H; Milheller P; Feagan B; D'Haens G; Marteau P; Reinisch W; Sturm A; Steinwurz F; Egan L; Panés J; Louis E; Colombel JF; Panaccione R
    J Crohns Colitis; 2013 Sep; 7(8):653-69. PubMed ID: 23562672
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 'Treat to Target' - Lessons Learnt.
    Kurti Z; Vegh Z; Golovics PA; Lakatos PL
    Dig Dis; 2016; 34(1-2):147-52. PubMed ID: 26981855
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enteral feeding in inflammatory bowel disease.
    Griffiths AM
    Curr Opin Clin Nutr Metab Care; 2006 May; 9(3):314-8. PubMed ID: 16607134
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Evolving Therapeutic Strategies in the Inflammatory Bowel Disease].
    Na SY; Moon W
    Korean J Gastroenterol; 2018 Feb; 71(2):61-68. PubMed ID: 29471602
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changing treatment paradigms for the management of inflammatory bowel disease.
    Im JP; Ye BD; Kim YS; Kim JS
    Korean J Intern Med; 2018 Jan; 33(1):28-35. PubMed ID: 29334728
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target.
    Peyrin-Biroulet L; Sandborn W; Sands BE; Reinisch W; Bemelman W; Bryant RV; D'Haens G; Dotan I; Dubinsky M; Feagan B; Fiorino G; Gearry R; Krishnareddy S; Lakatos PL; Loftus EV; Marteau P; Munkholm P; Murdoch TB; Ordás I; Panaccione R; Riddell RH; Ruel J; Rubin DT; Samaan M; Siegel CA; Silverberg MS; Stoker J; Schreiber S; Travis S; Van Assche G; Danese S; Panes J; Bouguen G; O'Donnell S; Pariente B; Winer S; Hanauer S; Colombel JF
    Am J Gastroenterol; 2015 Sep; 110(9):1324-38. PubMed ID: 26303131
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Are we ready for top-down therapy for inflammatory bowel diseases: con.
    Herfarth H
    Expert Rev Gastroenterol Hepatol; 2007 Dec; 1(2):249-55. PubMed ID: 19072417
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical implications of mucosal healing in the management of patients with inflammatory bowel disease.
    Orlando A; Guglielmi FW; Cottone M; Orlando E; Romano C; Sinagra E
    Dig Liver Dis; 2013 Dec; 45(12):986-91. PubMed ID: 23993738
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Faecal calprotectin assay after induction with anti-Tumour Necrosis Factor α agents in inflammatory bowel disease: Prediction of clinical response and mucosal healing at one year.
    Guidi L; Marzo M; Andrisani G; Felice C; Pugliese D; Mocci G; Nardone O; De Vitis I; Papa A; Rapaccini G; Forni F; Armuzzi A
    Dig Liver Dis; 2014 Nov; 46(11):974-9. PubMed ID: 25096964
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Appropriateness of immunosuppressive drugs in inflammatory bowel diseases assessed by RAND method: Italian Group for IBD (IG-IBD) position statement.
    Caprilli R; Angelucci E; Cocco A; Viscido A; Annese V; Ardizzone S; Biancone L; Castiglione F; Cottone M; Meucci G; Paoluzi P; Papi C; Sturniolo GC; Vecchi M
    Dig Liver Dis; 2005 Jun; 37(6):407-17. PubMed ID: 15893279
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Report: economic implications of inflammatory bowel disease and its management.
    Mehta F
    Am J Manag Care; 2016 Mar; 22(3 Suppl):s51-60. PubMed ID: 27269903
    [TBL] [Abstract][Full Text] [Related]  

  • 17. How Do We Treat Inflammatory Bowel Diseases to Aim For Endoscopic Remission?
    Dulai PS; Jairath V
    Clin Gastroenterol Hepatol; 2020 May; 18(6):1300-1308. PubMed ID: 31887449
    [TBL] [Abstract][Full Text] [Related]  

  • 18. What Are the Targets of Inflammatory Bowel Disease Management.
    Lega S; Dubinsky MC
    Inflamm Bowel Dis; 2018 Jul; 24(8):1670-1675. PubMed ID: 29697788
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
    Magro F; Portela F
    BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Implementing changes in clinical practice to improve the management of Crohn's disease.
    Panaccione R; Hibi T; Peyrin-Biroulet L; Schreiber S
    J Crohns Colitis; 2012 Feb; 6 Suppl 2():S235-42. PubMed ID: 22463930
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.